

KEYSTONE SYMPOSIA

on Molecular and Cellular Biology

HIV Vaccines (X7)

Scientific Organizers: Nicole A. Doria-Rose, Thumbi Ndung'u and Gunilla Karlsson Hedestam

Supported by the Directors' Fund

Functional Cures and the Eradication of HIV (X8)

Scientific Organizers: Lynn Morris, Melanie M. Ott and Kevin V. Morris

March 24-28, 2019 • Fairmont Chateau Whistler • Whistler, British Columbia, Canada

Sponsored by Gilead Sciences, Inc.

Global Health Travel Award Deadline: October 23, 2018 / Abstract & Scholarship Deadline: November 28, 2018 / Abstract Deadline: December 18, 2018 / Discounted Registration Deadline: January 24, 2019

SUNDAY, MARCH 24

Arrival and Registration

MONDAY, MARCH 25

Welcome and Keynote Session (Joint)

John R. Mascola, NIAID, National Institutes of Health, USA
Progress in HIV Vaccines

Robert F. Siliciano, Johns Hopkins University School of Medicine, USA
New Insights into the Extent and Dynamics of the Latent Reservoir

Antibodies for Prevention, Treatment and Cure (Joint)

David D. Ho, Aaron Diamond AIDS Research Center, USA
Engineering Antibodies to Combat HIV/AIDS

Florian Klein, University of Cologne, Germany
Broadly Neutralizing Antibodies for HIV-1 Immunotherapy

Short Talk(s) Chosen from Abstracts

Workshop 1 (X7)

Short Talks Chosen from Abstracts

Workshop 1 (X8)

Short Talks Chosen from Abstracts

Clinical Trials for Prevention: Vaccines and Antibodies (X7)

Glenda Gray, South African Medical Research Council, South Africa
ALVAC-gp120 for Clade C in South Africa

Lawrence Corey, Fred Hutchinson Cancer Research Center, USA
Validating Neutralization as a Mechanistic Surrogate of Protection in Passive Antibody Studies

Beatrice Ondondo, Cardiff Metropolitan University, UK
T-Cell Vaccine Trials

Short Talk Chosen from Abstracts

Development of the Innate Cell and Antibody Responses to HIV (X8)

Galit Alter, Ragon Institute of MGH, MIT and Harvard, USA
Harvesting Innate Immune Cell Function through Vaccination to Control Viral Replication

Michel C. Nussenzweig, HHMI/Rockefeller University, USA
Targeting B Lymphocytes to Control HIV-1

Lynn Morris, National Institute for Communicable Diseases, South Africa
Neutralizing Antibodies, Vaccines and Long-Term Control of HIV Infection

Short Talk Chosen from Abstracts

Poster Session 1

TUESDAY, MARCH 26

New Technologies for Studying and Inducing B Cells (X7)

Gunilla B. Karlsson Hedestam, Karolinska Institutet, Sweden
Antibody Germine Genes and Impact on Vaccine Responses

Speaker to be Announced

Adrian B. McDermott, National Institutes of Health, USA
Characterization of Antigen Specific Memory B Cells Following Vaccination

Colin Havenar-Daughton, La Jolla Institute of Allergy and Immunology, USA

Germinal Center Reactions in Vaccination

Short Talk(s) Chosen from Abstracts

Mechanisms of Viral Expression and Control of Host Cell Function (X8)

Saba Valadkhan, Case Western Reserve University, USA
Long Non-Coding RNAs Involved in HIV Latency and Reactivation

Eric M. Verdin, University of California, San Francisco, USA
CRISPR Based Characterizing of Latency-Associated Pathways

Jonathan Karn, Case Western Reserve University, USA
Signaling Pathways Controlling HIV Reactivation from Latency

Ivan D'Orso, UT Southwestern Medical Center, USA
Transcriptional Regulatory Mechanisms Shaping HIV Proviral Fate

Short Talk(s) Chosen from Abstracts

Antibody-Virus Coevolution: Vaccines and Lessons from Infection (X7)

Nicole A. Doria-Rose, NIAID, National Institutes of Health, USA
Broadly Neutralizing Antibodies: Lessons from Natural Infection

Mattia Bonsignori, Duke University Medical Center, USA
Multiple Maturation Pathways of the VRC01 Lineage Leading to Neutralization Breadth from the Fully Reverted Unmutated Common Ancestor

Elise Landais, International AIDS Vaccine Initiative, USA
Novel Antibody Lineages

Short Talk Chosen from Abstracts

Mechanism and Modulation of Latency (X8)

Melanie M. Ott, University of California, San Francisco, USA
Transcriptional Control of Viral Latency

Monsef Benkirane, Institut de Genetique Humaine, France
Biomarkers of Latency

Leor S. Weinberger, University of California, San Francisco, USA
Modeling of HIV Latency and Reactivation

Short Talk Chosen from Abstracts

KEYSTONE SYMPOSIA

on Molecular and Cellular Biology

HIV Vaccines (X7)

Scientific Organizers: Nicole A. Doria-Rose, Thumbi Ndung'u and Gunilla Karlsson Hedestam

Supported by the Directors' Fund

Functional Cures and the Eradication of HIV (X8)

Scientific Organizers: Lynn Morris, Melanie M. Ott and Kevin V. Morris

March 24-28, 2019 • Fairmont Chateau Whistler • Whistler, British Columbia, Canada

Sponsored by Gilead Sciences, Inc.

Global Health Travel Award Deadline: October 23, 2018 / Abstract & Scholarship Deadline: November 28, 2018 / Abstract Deadline: December 18, 2018 / Discounted Registration Deadline: January 24, 2019

Poster Session 2

WEDNESDAY, MARCH 27

Therapeutic Vaccines and Cure Strategies (Joint)

Thumbi Ndung'u, University of KwaZulu-Natal, South Africa
Treatment in Acute Infection: Lessons from the FRESH Cohort

Jintanat Ananworanich, US Military HIV Research Program, USA
Therapeutic Vaccines after Early ART: Impact on Viral Load Control Post Interruption

Beatriz Mothe, IrsiCaixa AIDS Research Institute-HIVACAT, Spain
Therapeutic Vaccines after Early ART: Impact on Reservoir

Warner Craig Greene, Gladstone Institute of Virology and Immunology, USA
Reversing HIV Latency by Activating AKT/mTOR Signaling

Short Talk(s) Chosen from Abstracts

T Cells in HIV Vaccination (X7)

Christian Brander, Institut de Recerca de la Sida, IrsiCaixa, Spain
Vaccine-Elicited T Cells in Clinical Trials

Jonah B. Sacha, Oregon Health & Science University, USA
Unconventional T Cells: Potential for Induction by Vaccination

David B. Masopust, University of Minnesota, USA
Tissue Resident T Cells

Short Talk Chosen from Abstracts

Experimental Molecular Approaches to Targeting Viral Reservoirs (X8)

Romas Geleziunas, Gilead Sciences, Inc., USA
Attacking Latent Reservoirs

Priti Kumar, Yale School of Medicine, USA
In vivo Gene Therapy and Nano-medicine to Treat HIV

Susana T. Valente, Scripps Florida, USA
Silencing the HIV-1 Reservoir

Short Talk Chosen from Abstracts

Poster Session 3

THURSDAY, MARCH 28

Env Immunogen Design and Evaluation (X7)

Richard T. Wyatt, IAVI Neutralizing Antibody Center at The Scripps Research Institute, USA
Modified HIV Trimers to Elicit Cross-Neutralizing Responses

Tongqing Zhou, NIAID, National Institutes of Health, USA
Opening and Closing Targets for Broadly Neutralizing Antibodies

Karin Loré, Karolinska Institutet, Sweden
In vivo Fate of Env and Early Responses upon Immunization

Derek T. O'Hagan, GSK Vaccines, USA
Designing and Building the Next Generation of Vaccine Adjuvants

Short Talk(s) Chosen from Abstracts

Targeting and Eradication of HIV (X8)

David M. Margolis, University of North Carolina at Chapel Hill, USA
Chemotherapeutic Control of Latency

Sharon R. Lewin, University of Melbourne, Australia
New Approaches to Eradicating HIV: Transitioning Experimental Therapeutics into Clinical Trials

Deborah Persaud, Johns Hopkins Hospital, USA
Latency and Viral Infection in Pediatrics

Lucy Dorrell, University of Oxford, UK
Novel Engineered Immune-Mobilizing T Cell Receptors-Based Drugs ('ImmTAVs') to Clear HIV Infection

Short Talk Chosen from Abstracts

Workshop 2 (X7)

Short Talks Chosen from Abstracts

Workshop 2 (X8)

Short Talks Chosen from Abstracts

From the Lab to the Clinic: A Reality Check for Investigators (X7)

Mark Connors, NIAID, National Institutes of Health, USA
Getting a Product to a Clinical Trial: The View from the Lab Bench

Hanneke Schuitemaker, Janssen Vaccines & Prevention B.V., Netherlands
Getting a Product to a Clinical Trial: The View from Industry

Speaker to be Announced

Protect and Kill Strategies to a Functional Cure (X8)

Paula M. Cannon, University of Southern California, Keck School of Medicine, USA
Genome Engineering Strategies to Generate HIV Resistant Cells

Scott G. Kitchen, University of California, Los Angeles AIDS Institute, USA
Engineering Long-Term HIV-Specific Immunity through Chimeric Antigen Receptors and Stem Cells

Kevin V. Morris, Center for Gene Therapy, City of Hope, USA
Cell Targeted Gene Modification and the Generation of HIV Targeted T-Cells

Meeting Wrap-Up: Outcomes and Future Directions (Organizers) (X7)

Meeting Wrap-Up: Outcomes and Future Directions (Organizers) (X8)

Meeting Wrap-Up: Outcomes and Future Directions (Organizers) (X8)

KEYSTONE SYMPOSIA

on Molecular and Cellular Biology

HIV Vaccines (X7)

Scientific Organizers: Nicole A. Doria-Rose, Thumbi Ndung'u and Gunilla Karlsson Hedestam

Supported by the Directors' Fund

Functional Cures and the Eradication of HIV (X8)

Scientific Organizers: Lynn Morris, Melanie M. Ott and Kevin V. Morris

March 24-28, 2019 • Fairmont Chateau Whistler • Whistler, British Columbia, Canada

Sponsored by Gilead Sciences, Inc.

Global Health Travel Award Deadline: October 23, 2018 / Abstract & Scholarship Deadline: November 28, 2018 / Abstract Deadline: December 18, 2018 / Discounted Registration Deadline: January 24, 2019

FRIDAY, MARCH 29

Departure